Arizona State Retirement System Raises Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Arizona State Retirement System boosted its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 33.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,088 shares of the company’s stock after buying an additional 3,297 shares during the quarter. Arizona State Retirement System’s holdings in SpringWorks Therapeutics were worth $478,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of SWTX. State Street Corp raised its position in SpringWorks Therapeutics by 143.7% in the 2nd quarter. State Street Corp now owns 3,889,249 shares of the company’s stock worth $95,753,000 after buying an additional 2,293,359 shares during the last quarter. BlackRock Inc. raised its position in SpringWorks Therapeutics by 31.3% in the 2nd quarter. BlackRock Inc. now owns 4,259,391 shares of the company’s stock worth $111,681,000 after buying an additional 1,015,359 shares during the last quarter. Dimensional Fund Advisors LP raised its position in SpringWorks Therapeutics by 191.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 795,463 shares of the company’s stock worth $20,475,000 after buying an additional 522,571 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of SpringWorks Therapeutics by 121,682.7% during the 2nd quarter. Point72 Asset Management L.P. now owns 463,992 shares of the company’s stock valued at $12,166,000 after purchasing an additional 463,611 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of SpringWorks Therapeutics by 16.5% during the 3rd quarter. Vanguard Group Inc. now owns 3,196,045 shares of the company’s stock valued at $91,184,000 after purchasing an additional 451,928 shares during the last quarter.

Insiders Place Their Bets

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $50.10, for a total value of $751,500.00. Following the completion of the transaction, the insider now directly owns 45,212 shares in the company, valued at approximately $2,265,121.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.61% of the stock is currently owned by corporate insiders.

SpringWorks Therapeutics Trading Down 5.6 %

Shares of NASDAQ:SWTX opened at $40.10 on Friday. The stock has a 50 day moving average of $47.96 and a 200 day moving average of $37.07. The company has a market cap of $2.96 billion, a PE ratio of -7.80 and a beta of 0.83. SpringWorks Therapeutics, Inc. has a 12-month low of $18.00 and a 12-month high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.20). The company had revenue of $5.45 million during the quarter, compared to the consensus estimate of $1.26 million. During the same period in the previous year, the business posted ($1.19) EPS. Equities research analysts predict that SpringWorks Therapeutics, Inc. will post -4.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on SWTX shares. Wedbush upped their price target on shares of SpringWorks Therapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Monday, February 26th. JPMorgan Chase & Co. upped their price target on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright upped their price target on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Guggenheim started coverage on shares of SpringWorks Therapeutics in a research report on Monday, February 5th. They set a “buy” rating and a $75.00 price target for the company. Finally, Barclays upped their price target on shares of SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $68.00.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.